These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37515190)

  • 21. Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.
    Inchingolo AD; Malcangi G; Ceci S; Patano A; Corriero A; Vimercati L; Azzollini D; Marinelli G; Coloccia G; Piras F; Barile G; Settanni V; Mancini A; De Leonardis N; Garofoli G; Palmieri G; Isacco CG; Rapone B; Scardapane A; Curatoli L; Quaranta N; Ribezzi M; Massaro M; Jones M; Bordea IR; Tartaglia GM; Scarano A; Lorusso F; Macchia L; Larocca AMV; Aityan SK; Tafuri S; Stefanizzi P; Migliore G; Brienza N; Dipalma G; Favia G; Inchingolo F
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.
    Fiedler S; Piziorska MA; Denninger V; Morgunov AS; Ilsley A; Malik AY; Schneider MM; Devenish SRA; Meisl G; Kosmoliaptsis V; Aguzzi A; Fiegler H; Knowles TPJ
    ACS Infect Dis; 2021 Aug; 7(8):2362-2369. PubMed ID: 33876632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.
    Crawford KHD; Eguia R; Dingens AS; Loes AN; Malone KD; Wolf CR; Chu HY; Tortorici MA; Veesler D; Murphy M; Pettie D; King NP; Balazs AB; Bloom JD
    Viruses; 2020 May; 12(5):. PubMed ID: 32384820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
    Konwarh R
    Front Immunol; 2020; 11():1531. PubMed ID: 32655584
    [No Abstract]   [Full Text] [Related]  

  • 25. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.
    Valdovino-Navarro BJ; Dueñas S; Flores-Acosta GI; Gasperin-Bulbarela J; Bernaldez-Sarabia J; Cabanillas-Bernal O; Cervantes-Luevano KE; Licea-Navarro AF
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective neutralizing epitopes in SARS-CoV-2.
    Liu H; Wilson IA
    Immunol Rev; 2022 Sep; 310(1):76-92. PubMed ID: 35599305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
    Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
    Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
    Tan CW; Chia WN; Qin X; Liu P; Chen MI; Tiu C; Hu Z; Chen VC; Young BE; Sia WR; Tan YJ; Foo R; Yi Y; Lye DC; Anderson DE; Wang LF
    Nat Biotechnol; 2020 Sep; 38(9):1073-1078. PubMed ID: 32704169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
    Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
    Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
    Hurlburt NK; Seydoux E; Wan YH; Edara VV; Stuart AB; Feng J; Suthar MS; McGuire AT; Stamatatos L; Pancera M
    Nat Commun; 2020 Oct; 11(1):5413. PubMed ID: 33110068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts.
    Adams O; Andrée M; Hermsen D; Lübke N; Timm J; Schaal H; Müller L
    J Virol Methods; 2022 Sep; 307():114569. PubMed ID: 35724697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of Neutralizing Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 by the Screening with Exosomes Expressing the Viral Spike Protein.
    Okada C; Ikeda-Ishizaka E; Ono C; Matsuura Y; Sonoda H
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):173-180. PubMed ID: 36027043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
    Lai R; Zhou T; Xiang X; Lu J; Xin H; Xie Q
    Front Med; 2021 Aug; 15(4):644-648. PubMed ID: 33909259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.